This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



IN THE UNITED STATES PATENTAND TRADEMARK OFFICE

Application No.:

10/036,208

Filed:

October 29, 2001

1st Inventor:

ODAKA, H. et al.

For:

Pharmaceutical Composition

Atty. Dkt. No.

2530 US1P

Art Unit:

1614

Examiner:

Allowed:

Batch:

Paper No.:

REQUEST TO CORRECT FILING DATE AND FILING RECEIPT

OIPE

Customer Service Center Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants have noted errors in the Filing Receipt for this application.

Filing Date:

Please change [12/29/2001] to read instead - - 10/29/2001 - -

Atty Docket No.:

Please change [2530 USA1P] to read instead - -2530 US1P- -

Title:

Please insert after "Pharmaceutical Composition" - -for the treatment of diabetes- -

REMARKS

I. Certificate of Mailing under 37 CFR 1.10 dated 10/29/2001

Applicants herewith enclose a copy of the Certificate of Mailing under 37 CFR 1.10 showing the date of deposit of the present application papers on 10/29/2001, signed by Gail Winokur.

III. Express Mail Receipt #EL 792689035 US Date In 10/29/2001

Applicants herewith enclose a copy of the Express Mail Receipt #EL 792689035 US showing the Date In as 10/29/2001 by the Lincolnshire Post Office.

#4

III. Return Postcard Showing Incorrect Filing Date

Applicants also enclose a copy of the return receipt postcard marked with the wrong filing date. Applicants were informed by phone to await issue of the Filing Receipt before requesting correction of the error.

A marked-up copy of the Filing Receipt is enclosed.

Conclusion

In view of the supporting documentation, Applicants respectfully request that the correct filing date of 10/29/2001 be assigned to the above-identified application. Applicants request that the requested corrections in the filing receipt be made and a Corrected Filing Receipt issued.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, she is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: February 19, 2002

(847)383-3372 (847)383-3391 Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA



FEB 1 9 2000

COMMISSIONER FOR PATENTS STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING DATE

GRP ART UNIT 1614

FIL FEE REC'D

ATTY.DOCKET.NO

TOT CLAIMS

IND CLAIMS

10/036,208

12/29/2001

740

10/29/2001

CONFIRMATION NO. 4444

FILING RECEIPT

DRAWINGS

OC000000007424399

23115 TAKEDA PHARMACEUTICALS NORTH AMERICA, INC INTELLECTUAL PROPERTY DEPARTMENT 475 HALF DAY ROAD SUITE 500 LINCOLNSHIRE, IL 60069

Date Mailed: 02/05/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Hiroyuki Odaka, Hyogo, JAPAN; Masahiro Yamane, Osaka, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/380,059 08/25/1999 PAT 6,329,403 WHICH IS A 371 OF PCT/JP99/03496 06/29/1999

Foreign Applications

JAPAN 10-183700 06/30/1998

If Required, Foreign Filing License Granted 02/05/2002

Projected Publication Date: 05/16/2002

Non-Publication Request: No

Early Publication Request: No

Title

Pharmaceutical composition

Pharmaceutical Composition For The Treatment of

Preliminary Class Diabetes

THE 1 9 2002 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

tba

Filed:

tba

1st Inventor:

H. ODAKA.

For:

Pharmaceutical Composition For The Treatment of Diabetes

Atty. Dkt. No.

2530 US1P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

. .

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 792689035 US

DATE IN:

October 29, 2001

Itemized Papers/Items:

- 1. This certificate and a Return Receipt Postcard (2 pages.)
- 2. Transmittal Form (1 page) + Fee Transmittal (1 page X2)
- 3. Specification 40 total pages, including Claims 1-21 (3 pages.), Abstract (1 page)]
- 4. First Preliminary Amendment (9 pages)
- 5. Executed Declaration/Power of Attorney (3 pages) (copy)
- 6. Information Disclosure Statement (1 page) with Form PTO 1449 (2 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

BOX Patent Application Commissioner for Patents Washington, D.C. 20231.

on this date, October 29, 2001

Dated: 10/29/01

Gail L. Winokur





tba tba

Application No.: Filed: is Inventor:

H. ODAKA

For:

Pharmaceutical Composition for the Treatment of Batch:

Diabetes

2530 US1P Atty Dkt. No.

Art Unit: Examiner:

tba Allowed:

Paper No.

The USPTO is requested to kindly acknowledge receipt of the following items:

1. This Postcard and Certificate of Express Mailing (2 pages)

- 2. Transmittal Form (1 page) + Fee Transmittal (1 page X 2)
- 3. Specification 40 total pages, including Claims 1-21 (3 pages), Abstract (1 page)]
 4. First Preliminary Amendment (9 pages)
- 5. Executed Declaration/Power of Attorney (3 pages) (copy)
- 6. Information Disclosure Statement (1 page) with Form PTO 1449 (2 pages)

Respectfully submitted 10/29/01 For Customer No. 23,115 Express Mail Label No. EL 792689035 IS By Mark Chao, PhD, JD - Reg. No. 37,293



02-20-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication No.:

10/036,208

Filed:

October 29, 2001

1st Inventor:

ODAKA, H. et al.

For:

Pharmaceutical Composition

Atty. Dkt. No.

2530 US1P

Art Unit:

1614

Evaminer:

41. .

Allowed:

Dotoh

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 916493064 US

DATE IN:

February 19, 2002

Itemized Papers/Items:

1. This certificate and a Return Receipt Postcard (2 pgs.)

2. Transmittal Form (1 pg. X 2)

3. Request to Correct Filing Date and Filing Receipt, and copy of Filing Receipt (6 pgs.)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231.

on this date, 2/19/02

Dated: 2/19/02

Gail L. Winokur



PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM		Application Number	10/036,208
		Filing Date	October 29, 2001
		First Named Inventor	ODAKA, H.
TRADE used for all correspondence after initial filing)		Group Art Unit	1614
		Examiner Name	tba
Total Number of Pages in This Submission 10		Attorney Docket Number	2530 US1P
ENCLOSURES (check all that apply)			
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(Extension of Time Request Express Abandonment Request Information Disclosure State Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing under 37 CFR 1.52 or	Drawing Licensin Petition Provisic Change Address Termina Reques ement CD, Nu Remarks	to Convert to a small Application of Attorney, Revocation of Correspondence is al Disclaimer st for Refund sumber of CD(s)	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Return Postcard. Certificate of Express Mailing Request to Correct Filing Date & Filing Receipt + copies of attachments. er is hereby authorized to onal fees which may be any overpayment to 500799.
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name Mark Chao, Ph.D., JD, Reg. No. 37,293			
Signature 2/1.			
Date 2/19/02			
CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first classemail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:			
Typed or printed name Gail L. Winokur Signature Gail L. Winokur Date 2/19/02			e 2/19/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.